Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Alessio Aligi Cogoni et al.|The Lancet Oncology|2018Cited by 88
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 studyMarina Elena Cazzaniga, Massimiliano Mazza, G. Pinotti et al.|The Breast|2019Cited by 58
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 studyMarina Elena Cazzaniga, I. Vallini, Emilia Montagna et al.|Breast Cancer Research and Treatment|2021Cited by 17
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patientsB. Trevisan, Francesca Fulvia Pepe, I. Vallini et al.|Scientific Reports|2023Cited by 5
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.Francesco Perrone, Ciro Gallo, Giancarlo Bisagni et al.|Journal of Clinical Oncology|2017Cited by 4